middle.news
Neurizon Secures $6M R&D Rebate to Power ALS Trial in 2026
1:32pm on Thursday 29th of January, 2026 AEDT
•
Biotechnology
Read Story
Neurizon Secures $6M R&D Rebate to Power ALS Trial in 2026
1:32pm on Thursday 29th of January, 2026 AEDT
Key Points
Secured $6 million cash rebate at 48.5% rate for FY2025
Rebate covers eligible R&D activities in Australia and overseas
Received $4.35 million net cash after financing and loan settlement
Funds to support HEALEY ALS Platform Trial starting Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE